Gregory Wu

Dr. Wu leverages more than 20 years of global biopharmaceutical experience and is a leader in structure-based drug design (SBDD) and medicinal chemistry with deep expertise in oncology and immuno-oncology. Dr. Wu served as CEO from 2019 to 2022 and CSO in 2018 at Nerviano Medical Sciences (NMS). Under his leadership, NMS advanced five NCEs into clinical trials globally. Prior to NMS, he held positions of increasing responsibility within Plexxikon-a Daiichi Sankyo comapny, Sugen-Pharmacia, Renovis and Coulter Pharmaceuticals-Corixa Inc. He made significant contributions to drugs garnering regulatory approval including Pexidartinib and Vemurafenib, as well as contributions to teams in launching Sunitinib and Tositumomab. He is an inventor of over 50 patents and co-author of publications in high-ranking journals including Nature, JAMA and PNAS. He holds a PhD in Organic Chemistry from Princeton University, an MS in Organic Chemistry and a BS in Chemistry from Fudan University.

Dr. Wu serves as Chief Executive Officer and member of the Board of Directors at NMS s.r.l. He leverages more than 20 years of global biopharmaceutical leadership and experience, as well as years of academic experience as a faculty member at Fudan University.
Before joining NMS Srl, he was Chief Scientific Officer at Lyrea Therapeutics, a startup with cutting-edge technologies. He also co-founded Xian-Feng Pharmaceuticals, Inc., an oncology-focused pharmaceutical company. Prior to Lyrea Therapeutics, he was Principal Scientist at Plexxikon where he led a team through a critical stage of growth from KSD and project initiation to advancing a number of projects into clinical trials. Before joing Plexxikon, he held positions of increasing responsibility with Sugen-Pharmacia, Renovis and Coulter-Corixa. He has made significant contributions to drugs garnering regulatory approval including Pexidartinib and Vemurafenib, as well as contribution to teams in launching Sunitinib and Tositumomab. He is an inventor of numerous patents and co-author on a numer of publications, including Nature and PNAS articles. He holds a PhD in Organic Chemistry from Princeton University, an MS in Organic Chemistry and a BS in Chemistry from Fudan University.